Loading...
•
Dec 31, 2021
CareDx Q4 2021 Earnings Report
CareDx's Q4 2021 results reflected revenue growth, driven by testing services and strategic acquisitions, but also showed increased net losses compared to the previous year.
Key Takeaways
CareDx reported a 35% increase in revenue for Q4 2021, reaching $79.2 million, driven by growth in testing services, product revenue, and patient and digital solutions. The company's net loss increased to $16.2 million, compared to a net loss of $3.5 million in the same period of 2020. AlloSure and AlloMap patient results grew by 67% year-over-year, and the company launched AlloSure Lung testing service. CareDx completed acquisitions of MedActionPlan and The Transplant Pharmacy.
Total revenue reached $79.2 million, a 35% increase year-over-year.
Approximately 41,900 AlloSure and AlloMap patient results were delivered, a 67% increase year-over-year.
AlloSure Lung testing service was launched, processing approximately 700 tests.
Acquisitions of MedActionPlan and The Transplant Pharmacy were completed.
Revenue by Segment
Forward Guidance
CareDx expects revenue to be in the range of $330 million to $350 million for the full year 2022.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...